title: Methotrexate for rheumatoid arthritis patients who are on hemodialysis.
abstract: Methotrexate (MTX) can be toxic to patients suffering from end stage renal disease (ESRD) on hemodialysis even at low doses. This increase in toxicity is more notable in terms of bone marrow suppression in the form of pancytopenia. Many methods of elimination including dialysis itself have been proven ineffective, and alternate treatments with anti-TNF alpha blockers can be considered.
authors.affiliation: Barts and The London School of Medicine and Dentistry, Turner Street, London, E1 2AD, UK.
authors.forename: Hasanein
authors.initials: H
authors.lastname: Al-Hasani
authors.forename: Euthalia
authors.initials: E
authors.lastname: Roussou
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D001853:Bone Marrow / Q000187:drug effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000503:physiopathology*; D008727:Methotrexate / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D010198:Pancytopenia / Q000139:chemically induced; D006435:Renal Dialysis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D028761:Withholding Treatment
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D008727:Methotrexate